M. Delaunay

3.8k total citations
50 papers, 1.8k citations indexed

About

M. Delaunay is a scholar working on Oncology, Dermatology and Epidemiology. According to data from OpenAlex, M. Delaunay has authored 50 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 20 papers in Dermatology and 13 papers in Epidemiology. Recurrent topics in M. Delaunay's work include Cutaneous lymphoproliferative disorders research (17 papers), Cutaneous Melanoma Detection and Management (13 papers) and Lymphoma Diagnosis and Treatment (12 papers). M. Delaunay is often cited by papers focused on Cutaneous lymphoproliferative disorders research (17 papers), Cutaneous Melanoma Detection and Management (13 papers) and Lymphoma Diagnosis and Treatment (12 papers). M. Delaunay collaborates with scholars based in France, United States and Germany. M. Delaunay's co-authors include M. Beylot‐Barry, B. Guillot, Brigitte Dréno, P Souteyrand, Catherine Lok, Jean‐Jacques Grob, S. Dalac, J J Bonerandi, B. Vergier and L. Machet and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

M. Delaunay

47 papers receiving 1.8k citations

Peers

Countries citing papers authored by M. Delaunay

Since Specialization

Citations

This map shows the geographic impact of M. Delaunay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Delaunay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Delaunay more than expected).

Fields of papers citing papers by M. Delaunay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Delaunay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Delaunay. The network helps show where M. Delaunay may publish in the future.

Co-authorship network of co-authors of M. Delaunay

This figure shows the co-authorship network connecting the top 25 collaborators of M. Delaunay. A scholar is included among the top collaborators of M. Delaunay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Delaunay. M. Delaunay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	États d’âme en réanimation COVID-19 : des émotions aux devoirs moraux des acteurs du soin 2021 ·Éthique & Santé ·(unknown), (unknown), M. Delaunay, (unknown)	1
2	Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy 2018 ·Acta Dermato Venereologica ·Laura Keller, Nicolas Guibert, Alfredo G. Casanova, Stéphanie Brayer, Mauro Farella, M. Delaunay, Julia Gilhodes, E. Martin, G Balagué, Gilles Favre, Anne Pradines, Nicolás Meyer	23
3	Neoadjuvant chemotherapy: a new criterion for selection of candidate patients for surgery of low tumour burden metastases from malignant melanoma? 2010 ·British Journal of Dermatology ·Thomas Jouary, Céline Legros, (unknown), (unknown), Khaled Ezzedine, B. Vergier, M. Delaunay, Jean-François Velly, Alain Taı̈eb	3
4	Le porocarcinome eccrine : une tumeur annexielle cutanée maligne hautement agressive 2008 ·Annales de Dermatologie et de Vénéréologie ·(unknown), Sébastien Lepreux, Alain Taı̈eb, M. Delaunay, T. Jouary	2
5	Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type 2007 ·Archives of Dermatology ·Florent Grange, M. Beylot‐Barry, (unknown), E. Maubec, Martine Bagot, B. Vergier, P Souteyrand, L. Machet, S. Dalac, É. Estève, I. Templier, Éric Delaporte, Marie‐Françoise Avril, Caroline Robert, Stéphane Dalle, L. Laroche, M. Delaunay, P. Joly, Janine Wechsler, Tony Petrella	144
6	A Case of Primary Cutaneous Nasal Type NK/T-Cell Lymphoma and Review of the Literature 2006 ·Dermatology ·(unknown), T. Jouary, B. Vergier, M. Delaunay, Alain Taı̈eb	20
7	Brain Magnetic Resonance Imaging in Patients With Cowden Syndrome 2005 ·Medicine ·Catherine Lok, (unknown), M.-F. Avril, M.‐A. Richard, Catherine Gondry‐Jouet, H. Deramond, (unknown), (unknown), M. Delaunay, F Piette, D. Legars, Brigitte Dréno, Philippe Saïag, Michel Longy, G. Lorette, L. Laroche, F. Caux	72
8	Clinical variants of the preprotuberant stage of dermatofibrosarcoma protuberans 2005 ·British Journal of Dermatology ·(unknown), F Piette, Philippe Blanc, Laurent Mortier, M. F. Avril, M. Delaunay, Brigitte Dréno, F Granel, F. Mantoux, F. Aubin, B. Sassolas, H. Adamski, S. Dalac, C. Pauwels, A. Dompmartin, Christianne Lok, É. Estève, B. Guillot, (unknown)	52
9	Cutaneous malignant melanoma and neurofibromatosis type 1 2004 ·Melanoma Research ·B. Guillot, S. Dalac, M. Delaunay, M. Baccard, J. Chevrant‐Breton, O. Dereure, L. Machet, B. Sassolas, J Zeller, Philippe Bernard, C. Bédane, P. Wolkenstein	41
10	Bone Marrow Histopathologic and Molecular Staging in Epidermotropic T-Cell Lymphomas 2003 ·American Journal of Clinical Pathology ·V. Sibaud, M. Beylot‐Barry, Rodolphe Thiébaut, Marie Parrens, B. Vergier, M. Delaunay, C Beylot, Geneviève Chêne, Jacky Ferrer, Antoine de Mascarel, Pierre Dubus, (unknown)	14
11	A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma 2003 ·Melanoma Research ·F. Mornex, L. Thomas, Peter Mohr, Axel Hauschild, M. Delaunay, Thierry Lesimple, Wolfgang Tilgen, B. Bui, B. Guillot, Jens Ulrich, S. Bourdin, M Mousseau, Didier Cupissol, (unknown), C. De Gislain, R.J. Bensadoun, M. Clavel	104
12	Essai de phase III randomisé comparant la fotémustine seule ou associée à une irradiation encéphalique dans les métastases cérébrales de mélanome† 2003 ·Cancer/Radiothérapie ·F. Mornex, L. Thomas, Peter Mohr, Axel Hauschild, M. Delaunay, Thierry Lesimple, Wolfgang Tilgen, Binh Bui Nguyen, B. Guillot, Jens Ulrich, S. Bourdin, M Mousseau, Didier Cupissol, Jacques Bonneterre, C. De Gislain, (unknown), M. Clavel	20
13	Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma 2001 ·European Journal of Cancer ·A Lafuma, Brigitte Dréno, M. Delaunay, Corinne Emery, Francis Fagnani, K Hieke, J J Bonerandi, Jean‐Jacques Grob	19
14	Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial 2001 ·British Journal of Cancer ·Alain Ravaud, M. Delaunay, Christine Chevreau, Vincent Coulon, Marc Debled, (unknown), F. Courbon, N. Gualde, (unknown)	15
15	Evidence that an Identical T Cell Clone in Skin and Peripheral Blood Lymphocytes is an Independent Prognostic Factor in Primary Cutaneous T Cell Lymphomas 2001 ·Journal of Investigative Dermatology ·M. Beylot‐Barry, V. Sibaud, Rodolphe Thiébaut, B. Vergier, C Beylot, M. Delaunay, Geneviève Chêne, Pierre Dubus, (unknown)	57
16	The Spectrum of Cutaneous Lymphomas in HIV Infection 1999 ·The American Journal of Surgical Pathology ·M. Beylot‐Barry, B. Vergier, Bernard Masquelier, Martine Bagot, Pascal Joly, P Souteyrand, Loı̈c Vaillant, Marie‐Françoise Avril, Nathalie Franck, (unknown), M. Delaunay, L. Laroche, É. Estève, Philippe Courville, Pierre Déchelotte, C Beylot, Antoine de Mascarel, Janine Wechsler, Jean‐Philippe Merlio	46
17	Melanoma and Tumor Thickness 1999 ·Archives of Dermatology ·M.‐A. Richard, Jean‐Jacques Grob, M.-F. Avril, M. Delaunay, Xavier Thirion, P. Wolkenstein, P Souteyrand, Brigitte Dréno, J J Bonerandi, S. Dalac, L. Machet, J. C. Guillaume, J. Chevrant‐Breton, C Vilmer, F. Aubin, B. Guillot, M. Beylot‐Barry, Catherine Lok, Nadia Raison‐Peyron, P. Chemaly	96
18	Statistical Evaluation of Diagnostic and Prognostic Features of CD30+ Cutaneous Lymphoproliferative Disorders 1998 ·The American Journal of Surgical Pathology ·B. Vergier, M. Beylot‐Barry, Karen Pulford, Patrik Michel, J. Bosq, A. De Muret, C Beylot, M. Delaunay, M. F. Avril, S. Dalac, Christine Bodemer, K.H. Ly, Alexis Groppi, A. de Mascarel, M. Bagot, David Y. Mason, Janine Wechsler, J.P. Merlio	68
19	Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases 1998 ·The Lancet ·Jean‐Jacques Grob, Brigitte Dréno, Pauline de La Salmonière, M. Delaunay, Didier Cupissol, B. Guillot, P Souteyrand, B. Sassolas, Jean‐Pierre Césarini, (unknown), Catherine Lok, Claude Chastang, J J Bonerandi	274
20	A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma 1995 ·British Journal of Cancer ·Alain Ravaud, E. Legrand, M. Delaunay, E Bussières, Vincent Coulon, Laurent Cany, Sylvie Huet, (unknown), Michèle Kind, François Chomy, (unknown), N. Gualde	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact